Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.
about
Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipidLife expectancy in Gaucher disease type 1Imiglucerase in the treatment of Gaucher disease: a history and perspectiveGaucher disease: the role of the specialist on metabolic bone diseasesImmunological cells and functions in Gaucher diseaseGaucher disease and comorbidities: B-cell malignancy and parkinsonismGaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolismEffects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and StabilityGaucher disease: transcriptome analyses using microarray or mRNA sequencing in a Gba1 mutant mouse model treated with velaglucerase alfa or imigluceraseA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsClinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher disease.Gaucher's disease: a paradigm for interventional genetics.An overview on bone manifestations in Gaucher disease.Coxarthritis as the presenting symptom of Gaucher disease type 1.Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease.Hematological manifestations and complications of Gaucher disease.Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease.TPL2 kinase regulates the inflammatory milieu of the myeloma nicheThe pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.Hyperferritinemia and iron overload in type 1 Gaucher disease.Common and uncommon pathogenic cascades in lysosomal storage diseasesBone and joint complications related to Gaucher disease.Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature.High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease.Gaucher disease: pathological mechanisms and modern management.Skeletal aspects of Gaucher disease: a review.Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patientsType II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammationFuture perspectives for glycolipid research in medicine.Severe impairment of regulatory T-cells and Th1-lymphocyte polarization in patients with Gaucher disease.The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.New macrophage models of Gaucher disease offer new tools for drug developmentActivation of p38 Mitogen-Activated Protein Kinase in Gaucher's DiseaseLysosomal storage disorders.Gaucher disease gene GBA functions in immune regulation.Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.
P2860
Q24320202-EA7AF8E7-C14B-49BC-9EF4-AABDD42238DDQ24631415-963D72A7-26D1-4833-9C58-2CFE54407DB6Q24631426-FCDC80FC-BC79-49E5-90DA-0CDCEC9111A8Q26775745-10CC4B17-E7DA-46BA-870A-9563840C9833Q26827675-E385B3E5-9DCA-484F-A1E7-4E3213778BEAQ27002301-F197BECD-32A9-4684-BF53-6160CE21953FQ27013427-9E5631EC-0684-4484-9D60-8B80BC35E93FQ27654912-4BB5A1EC-4EF9-4DA4-A79E-6E9A22B621A0Q28534109-35797E27-BBBC-4FA5-B149-64B4FB5E0AF1Q30235844-9835B338-81FE-4D3A-BE87-5E169B73B26CQ30544056-2E223C0C-14D8-46EC-BBF1-FB8B265D065EQ31146661-8D9C91FD-6E60-484C-B9D3-61438248FE78Q33358034-E1A81176-5DE5-4CCA-BF53-A18EAF1EACEFQ33359729-7012EE6C-E50C-4335-B777-228D5CD492E2Q33393590-4061978E-B331-4C72-BFC1-6264A4C933CBQ33397946-5F6D1C3F-4F20-477C-A5BA-D6DF771E81CDQ33406021-7AA93AC1-A67A-4818-91A4-3B25DF4468C4Q33427535-18C1EEEA-8AC1-4782-AE32-88FD33E5E595Q33659850-1456009E-1DCC-4FFF-A493-5E30D4A8C0F3Q33714724-EB6F928B-BA43-41ED-855E-AB5E28F1342FQ33870303-C09D5845-0C7B-42A0-A8E7-F91A2DB7891AQ33874873-52ABA2A4-4391-4FFD-A44E-482CB8DE3769Q33954790-B95C99F4-8798-4EF9-B40A-3F8B6C218C9DQ33966917-F3B6AB1D-2ECB-4498-9018-43C5CE8AB28AQ34108919-38CBBCE2-83D9-4502-8C6F-AE60DB2E4B3DQ34339886-072CC802-A3D8-4E6C-9938-09F75BE5D590Q34432886-F907054B-BB09-429E-AE93-C80EB5DAF178Q34556549-963AA8CF-50FE-436B-B92C-AA6AC4357425Q34661021-A419A738-FFBE-4EB3-941C-6A198B4B5E9EQ34791322-E3F7C2DE-3E78-42BF-9FCE-ED2E344A1C75Q34919711-CD9F51D2-3B40-4923-BB36-86B2B641B091Q35103549-44AAAE37-E360-4F92-9E8E-374F4CBF4598Q35153243-FD34C8AC-D7F4-493D-B574-51CB831CF7D5Q35183107-CBF55551-58F7-4F4C-AA8B-E081A1949D33Q35611123-2223BD3D-5B55-446B-B498-5F9313ED0B55Q35747464-95F344E5-DB3D-4E42-A7FF-D28347CBA598Q35757092-2E7345D8-644B-4714-B2E2-F669C30763FAQ36027312-4DA6A33F-9F30-4BE8-91B4-EDDD5AF06CCBQ36056642-76F331B5-2D3D-4A9C-98FC-42407C75F153Q36088711-62BB1A28-8410-4466-9A81-BFC571F6A126
P2860
Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@en
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@nl
type
label
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@en
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@nl
prefLabel
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@en
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@nl
P2093
P356
P1476
Pro-inflammatory cytokines and ...... erleukin-6 and interleukin-10.
@en
P2093
P356
10.1093/QJMED/90.1.19
P407
P577
1997-01-01T00:00:00Z